UNASSIGNED: 4139 Background: Postoperative chemoradiotherapy using bolus @entity1487 has recently been established as the standard treatment of @entity5 (Macdonald et. al., NEJM, 2001). Here we report the preliminary results of a modified "Macdonald" regimen, incorporating @entity3003 and utilizing the less toxic infusional @entity1487 regimen, in the adjuvant treatment for resected T3/T4 or node positive @entity356 . METHODS: 19 @entity1 underwent complete en bloc surgical resection and were treated with postoperative chemoradiotherapy for a total of 19 weeks. They received @entity1487 (200 mg/m2/day) via continuous IV infusion for weeks 1-6; @entity4181 (20 mg/m2) on days 1, 8, 15, 22, 29, 36; and @entity3003 (AUC 6) on days 1 and 22. This was followed by a one-week rest period. On week 8, @entity1 were re-started on infusional @entity1487 (200mg/m2/day) with daily radiotherapy administered with standard AP/PA fields to a total dose of 4500 cGy. One to two weeks after completion of their radiation, @entity1 then received an additional six weeks of chemotherapy identical to the first six weeks as tolerated. RESULTS: The overall and disease free survival for combined postoperative chemoradiotherapy was 58% (95% CI 37%-79%). Survival by stage was 80% (95% CI 63%-97%) for stage II (4 out of 5 @entity1 alive); 70% (95% CI 50%-90%) for stage IIIA/IIIB (7 out of 10 @entity1 alive); and 0% for stage IV disease (T3N3M0; 0 out of 4 @entity1 alive). 5 @entity1 died from recurrent disease (26%), 2 died from other (non-malignant) causes (10%), and one was lost to follow-up. Median follow-up was 19 months (range 6 to 72 months) and median survival has not yet been reached. The most common @entity137 was @entity1398 (29% grade 3, 6% Grade 2); @entity882 (12% grade 3, 18% grade 2); @entity417 (29% grade 2); and @entity3136 (12% grade 2, 18% grade 1). CONCLUSION: In @entity1 with advanced @entity356 (T3/T4 or node positive disease) the addition of adjuvant chemoradiotherapy improves overall survival when compared to surgery alone. This regimen of continuous infusion @entity1487 / @entity4181 / @entity3003 and radiotherapy was relatively well tolerated with an overall survival of 58% and a median survival that has not been reached. No significant financial relationships to disclose.

Adjuvant chemoradiotherapy for T3, T4, or node positive XXXX : A phase II trial.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity4181 :: ('MESH:D002955', 'Chemical') :: ['leucovorin'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity3136 :: ('MESH:D013280', 'Disease') :: ['stomatitis'] @entity417 :: ('MESH:D000740', 'Disease') :: ['anemia'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity5 :: ('MESH:D009369', 'Disease') :: ['Stage II/III gastric cancer'] @entity3003 :: ('MESH:D016190', 'Chemical') :: ['carboplatin'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity356 :: ('MESH:D013274', 'Disease') :: ['gastric cancer'] @entity1487 :: ('MESH:D005472', 'Chemical') :: ['5FU']
@entity356 :: (MESH:D013274,Disease) :: ['gastric cancer']
